Top 50 Ai For Genomics in LATAM

Onc.ai develops AI models leveraging oncology real-world data, including imaging, EMR, and genomics, to enhance precision oncology. The company's deep learning imaging AI aims to bring clarity to cancer treatment decision-making for medical oncologists. Initial products focus on predicting clinical outcomes in metastatic lung cancer to support pharmaceutical clinical development.

The startup specializes in identifying bioactive ribonucleic acid (RNA) from natural sources using machine learning and bioinformatics techniques. This enables researchers to enhance human health and resilience in response to environmental stressors through the application of RNA technologies.

Embryoxite develops an AI-powered platform that analyzes embryo metabolomic data, genetic profiles, and morphokinetic imaging to assess implantation potential in pre-implantation embryos. This technology addresses the high failure rate of embryo implantation in IVF procedures by providing objective, data-driven insights that enhance selection accuracy and improve pregnancy outcomes.

Clear Labs is a biotechnology firm that utilizes a genomics system to enhance diagnostic accuracy in clinical and application sectors. The company addresses the complexity of traditional diagnostic processes by providing streamlined genomic analysis, enabling faster and more reliable results.

Eugit develops novel tissue targeting therapies for complex diseases. The company leverages expertise in computational genomics and immunology to design precise therapeutic approaches. Their focus is on creating treatments that selectively engage specific biological targets within diseased tissues.

Biotango utilizes genomic editing and climate data analysis to enhance the productivity and quality of fruit crops, addressing the significant food waste and economic losses in agriculture. By predicting crop behavior under varying climatic conditions, the company aims to improve yield efficiency and reduce losses in fruit production by up to 30%.

Nintx develops next-generation pharmaceutical and nutraceutical therapies by translating complex intra- and interspecies biological interactions into novel treatments. The company leverages proprietary omics and data analytics technologies to discover natural product ingredients that modulate human biological targets and the gut microbiome. This platform focuses on creating multi-target solutions for multifactorial diseases linked to human biology and microbial crosstalk.

Elegen utilizes proprietary cell-free DNA synthesis technology to produce long, complex, linear DNA up to 7 kb with 99.999% accuracy, eliminating the need for cloning. This rapid synthesis, delivered in 6 to 8 business days, addresses the critical bottleneck in DNA supply for synthetic biology applications, significantly reducing project timelines and costs.

VivaWell provides a digital health and wellness platform that uses AI and data science to deliver personalized health programs and quality healthcare. It helps individuals and organizations improve health outcomes and manage healthcare costs through tailored services and population health insights.

Rosebud Biosciences develops targeted therapies for rare pediatric genetic diseases using patient-specific organoid models. The company engineers micropatterned 2.5D organoids from induced pluripotent stem cells that replicate individual genetic mutations for drug screening. This platform enables the high-throughput testing of small molecules, gene therapies, and RNA therapeutics against complex developmental disorders.

Huna develops an AI engine that analyzes routine blood test data to identify risk patterns for early cancer detection and other chronic diseases. This technology enables healthcare providers to classify patients by risk level, improving clinical decision-making and increasing the chances of successful treatment while reducing overall healthcare costs.

The startup has developed a molecular testing platform that utilizes low-cost tools for on-site analysis of DNA, RNA, and protein targets. This technology enables businesses to make real-time decisions regarding food quality and health by providing precise and accessible testing services.

Precision Data provides a business intelligence platform that utilizes generative artificial intelligence to optimize access to over 8 billion lines of structured clinical data, enhancing real-world evidence studies in healthcare. The company addresses the challenge of data quality and accessibility, enabling healthcare organizations to make informed decisions based on accurate and comprehensive information.

Comsentimento develops an AI-driven platform for clinical data transformation and research, focusing on enhancing cancer treatment and facilitating access to clinical trials. The platform provides healthcare professionals with actionable insights and support for chronic disease management, improving patient care and treatment adherence.

Arkangel AI is a no-code platform that transforms medical data into AI algorithms for early disease detection, enabling healthcare organizations to build and deploy tailored solutions efficiently. By streamlining processes such as patient triage and drug adverse effect prediction, Arkangel AI enhances healthcare outcomes while significantly reducing operational costs.

The startup has developed a clinical research platform that utilizes machine learning to target the biological processes of aging, facilitating the discovery of therapies for age-related diseases such as cardiovascular and neurodegenerative conditions. By enabling pharmaceutical companies to enhance medical treatments, the platform addresses the need for more effective interventions in aging-related health issues.

CellRep develops an AI-powered platform to discover and validate compounds for non-genetic cell reprogramming. This approach optimizes cellular function to enhance therapeutic potential, addressing limitations in current cell therapies like CAR-T treatments. The company provides an end-to-end pipeline from target discovery through preclinical validation for applications in oncology and longevity.

MEDiC utilizes a proprietary CRISPR functional genomics platform combined with 3D tumor models to identify cancer biomarkers and novel drug targets with high precision. This approach addresses the challenge of missed potential biomarkers in current drug development, enhancing the accuracy of patient stratification for oncology treatments.

Neocrop is an agro-biotech startup utilizing CRISPR gene editing and speed breeding techniques to develop resilient crop varieties that require fewer pesticides and offer enhanced nutritional value. By addressing the challenges of climate change and food security, Neocrop accelerates the creation of high-yield, drought-resistant seeds in record time, supporting the agricultural industry in Latin America.

metaBIX develops advanced computational tools for accelerating drug discovery pipelines. The platform integrates machine learning models with high-throughput screening data to predict compound efficacy and toxicity profiles. This capability allows pharmaceutical researchers to rapidly identify viable therapeutic candidates with optimized physicochemical properties.

Base Cientifica offers comprehensive molecular and cellular research services to accelerate preclinical development and personalized medicine. They specialize in biological assay validation, biobanking, and molecular diagnostic assay development using PCR and NGS. Their services also include preclinical efficacy and safety studies, 3D organoid cultivation, and AI-driven R&D optimization.

The startup operates a genomics platform that centralizes and integrates DNA data to provide precise diagnoses and personalized treatment plans through advanced data analysis and interpretation. By leveraging genomic information, the platform enables researchers to enhance health outcomes and preventive care strategies for individuals.

Beeing Company utilizes artificial intelligence and neural networks to perform genetic analysis of honey bee queens, ensuring the preservation of bee species and promoting biodiversity. Their certification process guarantees that beekeepers can verify the quality and health of their bees, facilitating access to international markets.

The startup develops AI-powered applications that enhance decision-making by analyzing large datasets and providing actionable insights. This technology enables organizations to make data-driven choices more efficiently, reducing uncertainty and improving operational outcomes.

The startup has developed a molecular diagnostic platform that integrates advanced fluidics, engineering, and bioinformatics to create a user-friendly in vitro diagnostic system. This technology enables healthcare providers to deliver precise clinical genomic information to patients, enhancing accessibility to essential diagnostics for improved treatment outcomes.

NeuroGeneces offers the NeuroInsight™ assessment, which utilizes biometric sensors and AI algorithms to detect atypical brain decline up to two decades before symptoms appear, enabling timely intervention. Additionally, the NeuroGevity system enhances memory consolidation by stimulating slow-wave sleep through synchronized sound, improving brain activity related to memory preservation.

This startup provides personalized medicines through genetic testing and data analysis, enabling microgram-level customization of treatments. By tracking the entire treatment journey, it offers patients affordable, tailored medications and real-time updates on their health status.

Diag-Nose.io develops the RhinoMAP platform to decode airway biology for respiratory diseases. This platform integrates nasal microsampling, proteomics, and machine learning algorithms to analyze biomarker data. The goal is to enable precision medicine by identifying root causes, leading to faster, more effective treatment selection for patients.

TAXON utilizes artificial intelligence and genomic analysis to enhance soil microbiome understanding, enabling farmers and biotech companies to optimize crop yields and reduce reliance on agrochemicals. By providing detailed insights into microbial diversity and functionality, TAXON helps clients make informed decisions that lead to sustainable agricultural practices and improved productivity.

Kinzbio develops phage-based precision antimicrobials to combat antibiotic-resistant infections quickly and effectively. Their platform utilizes AI-driven software and proprietary databases to deliver personalized, pharmaceutical-grade therapies within 5 to 15 days. The company also engineers solutions for infection prevention in clinical settings, targeting harmful bacteria with high specificity.

Entelai provides AI-driven diagnostic tools for the healthcare sector in Latin America, enhancing the accuracy of medical image analysis and optimizing physician workflows. Their solutions address the challenges of diagnostic precision and resource utilization, ultimately improving patient care and satisfaction.

The startup develops gene therapies utilizing a biocompatible delivery system to facilitate targeted treatment of genetic diseases. This approach enhances the efficacy of therapeutic interventions, addressing the limitations of traditional treatment methods in the biotechnological market.

The startup develops predictions-based artificial intelligence software that analyzes data to create accurate predictive models, minimizing human error. This technology enhances operational efficiency and competitiveness for clients across various business processes by transforming raw data into actionable insights.

Aperture Therapeutics develops oligonucleotide therapeutics by identifying naturally occurring gene variants that confer protection against neurodegenerative diseases. The platform uses machine learning to analyze genomic and clinical datasets to prioritize protective gene variants for therapeutic mimicry. This approach targets genetically validated pathways to address shared drivers in ALS and FTD, expanding patient applicability beyond rare mutations.

Longlife provides personalized healthcare by integrating genomics, microbiomics, epigenomics, and metabolomics through its GeneBiom 360° Test. This analysis informs the creation of custom probiotics and postbiotics designed to restore microbial balance and optimize metabolic pathways. The company focuses on delivering precision medication and tailored biotic solutions to address chronic disease at its biological root.

Epinoma develops a CRISPR-based epigenetic blood test that detects early signs of cancer and neurodegenerative diseases, providing a more precise alternative to traditional imaging and protein marker methods. This technology enhances patient stratification strategies in clinical settings, enabling oncologists to make informed decisions for late-stage colorectal cancer patients.

Rarus Health provides a digital platform that assists families with rare genetic diseases by offering personalized care plans and access to a multidisciplinary team of healthcare professionals. The platform streamlines the diagnostic process and treatment coordination, while generating validated data for pharmaceutical research and development.

This startup has developed a biotech platform that enhances the drug discovery process through predictive toxicology and drug quality assurance, specifically tailored for the Latin American market. By optimizing research and development workflows, the platform reduces time and costs while minimizing the reliance on animal testing.

Inkus provides genetic and genomic solutions to enhance the productivity and resilience of aquaculture species through precision breeding techniques. The startup addresses the challenges of low yield and vulnerability to disease in the aquaculture industry, enabling sustainable growth and improved stock performance.

Multiplex.bio offers advanced molecular diagnostics for plant viruses and viroids using high-throughput sequencing and its proprietary Viroscope™ algorithm. This platform provides high diagnostic certainty by correlating viral genome coverage with biological infectivity, ensuring accurate detection for plant health management.

OmniTier Storage provides on-premise genomic analysis appliances that utilize AI-based variant interpretation to enhance the accuracy and speed of diagnosing rare genetic diseases. By automating secondary analysis and supporting multiple sequencing technologies, the platform enables researchers and clinicians to efficiently implement custom methodologies while maintaining control over patient data and reducing costs.

This healthcare platform uses AI to analyze a patient's complete medical history, including medications and exam results, to generate intelligent diagnostic hypotheses. It helps medical professionals formulate accurate diagnoses by feeding patient characteristics into an algorithm, streamlining the diagnostic process.

MYNU is a biotechnology startup that utilizes genetic testing to analyze over 130 genes, creating personalized nutrition plans tailored to individual genetic profiles. By combining biotechnological research and artificial intelligence, MYNU addresses the need for customized dietary solutions that enhance personal well-being and support specific health goals.

The startup utilizes a proprietary Generative Biology Platform and a Discovery Platform that integrate machine learning and multi-modal single-cell analysis to identify gene regulatory networks and develop targeted cell therapies for cancer. By precisely modulating gene expression in specific cell types, the company aims to enhance the efficacy of cell-based treatments, addressing the limitations of traditional cancer therapies.

Naturannova utilizes a computational platform that combines AI and bioinformatics to identify and analyze plant-based proteins, creating sustainable and clean label ingredients. The startup addresses the need for healthier food options by developing novel protein sources, such as their all-natural protein-based sweetener, through precision fermentation and laboratory testing.

Petgenoma provides canine genetic testing services using advanced DNA analysis to identify breed composition, health predispositions, and behavioral traits. Their platform offers detailed insights into over 300 disease markers and genetic factors influencing behavior, empowering pet owners and veterinarians with actionable data for personalized care.

The startup develops a DNA-based affinity test kit that analyzes genetic variants affecting drug metabolism, enabling personalized treatment plans for patients. This approach minimizes adverse drug reactions and enhances therapeutic efficacy by tailoring medications to individual genetic profiles.

Gbot develops a high-throughput phenotyping platform that utilizes autonomous ground vehicles and AI to automate data collection and analysis for crop characterization. This technology addresses the limitations in plant breeding by providing accurate, large-scale crop information essential for enhancing global food production.

The startup provides customizable, scalable AI models via API integration for open-pit industries, enhancing operational efficiency and decision-making processes. Their technology addresses the need for tailored data solutions that seamlessly fit into existing business workflows.

mDETECT develops a DNA-methylation-based liquid biopsy technology that enables oncologists to accurately assess tumor burden and monitor treatment response in metastatic breast cancer patients. This technology provides detailed, personalized data on cancer progression and relapse, facilitating more effective patient management.